Study to Investigate the Immune Response to Influenza Vaccine in Patients With Multiple Sclerosis on Teriflunomide
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
Primary Objective:
Assess the antibody response to influenza vaccine in patients with relapsing form of multiple
sclerosis (RMS) treated with teriflunomide compared to a reference population.
Secondary Objectives:
- Assess the effect of teriflunomide on immunoglobulin levels;
- Assess the safety of influenza vaccination in patients with RMS treated with
teriflunomide.
The reference population was defined as multiple sclerosis (MS) patients with a stable
treatment with interferon-β-1. Antibody response was measured using hemagglutination
inhibition assay (HIA) and the hemagglutinin antigens representing the stains of H3N2, H1N1,
and B as present in the influenza vaccine used.